DRUGBRIGHT MINDS BIOSCIENCES INC.
Next earnings Aug 12, 2026
$77.84
▼ -0.46%$77.84▲ +184.82%
over 1Y
L $24.36H $95.99
Today
-0.5%
1W
+16.8%
1M
+26.4%
3M
-6.8%
YTD
-6.7%
1Y
+184.8%
Sell
Conviction
Horizon
Medium (3–12mo)
Street · 7 analysts
Buy
Mixed signals in the latest filings.
This call stands until the filings change it — the engine re-rates on new 10-K/10-Q/8-K facts, never on price moves. Hit Watch above to follow DRUG (Pro alerts fire the moment a rating flips), or catch every change in Saturday’s Flip Side. How to read a call
BRIGHT MINDS BIOSCIENCES INC. shows limited reported revenue.
On these fundamentals, DRUG screens as SELL on the SEC figures.
Is DRUG a buy? The one-page verdict, explained →
The options angle
model · matches our verdictBear put spread~60d expiry
- Long put 78 @ ~9.04 est
- Short put 70 @ ~5.21 est
debit $383max +$417max −$383BE 74.17
SELL verdict, defined risk: profits into weakness down to the short strike; max loss is the net debit.
Educational template, not a trade recommendation. Strikes and premiums are Black-Scholes model estimates from the last close and 30-day realized volatility — real chains, spreads and IV will differ. Options involve substantial risk.
Financialsannual, by fiscal year
No income data filed.
10-year statements — income, cash flow, balance sheet & CSV export →
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Key statistics
Valuation
Enterprise value$767M
EV / EBITDA—
EV / Sales—
EV / FCF—
P / FCF—
PEG (trailing)—
Earnings yield—
FCF yield—
Quality & risk
ROIC (est.)—
Free cash flow—
Total debt—
Net cash—
Capital returns
Buyback yield—
Dividend yield (est.)—
Shareholder yield—
Shares Δ YoY+1.3%
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
Recent filings
all on EDGAR ↗SCHEDULE 13D/AFiling2026-07-02open ↗6-KPeriod ending 2026-03-312026-06-03open ↗6-KPeriod ending 2026-01-202026-06-02open ↗6-KPeriod ending 2026-05-262026-05-28open ↗6-KPeriod ending 2026-03-312026-05-20open ↗SCHEDULE 13GFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-15open ↗SCHEDULE 13G/AFiling2026-05-12open ↗SCHEDULE 13G/AFiling2026-04-30open ↗4Period ending 2026-04-282026-04-30open ↗SCHEDULE 13G/AFiling2026-02-17open ↗
Frequently asked
- Is BRIGHT MINDS BIOSCIENCES INC. (DRUG) a buy?
- DRUG currently carries a Sell rating with 2/5 conviction, derived from its latest SEC filings. Mixed signals in the latest filings.
- What is BRIGHT MINDS BIOSCIENCES INC.'s quality score?
- DRUG scores 71.80630861040068/100 (grade B) on a SEC-grounded quality model spanning value, growth, profitability, financial health and momentum.
Sources: SEC EDGAR (CIK 0001827401, latest SCHEDULE 13D/A filed 2026-07-02) · EODHD · as of 7/11/2026, 10:42:11 AM.
About this recommendation — produced by TENK/calls (tenkcalls.com), Luxembourg · not investment advice
Rule-based analysis, generated automatically from SEC filing data.
Investment recommendation produced by TENK/calls (tenkcalls.com), Luxembourg. Completed Jul 11, 2026, 6:42 AM ET. Ratings & methodology: definitions · All recommendations to date: track record · Conflicts: disclosures. Not investment advice.
Research and education only — not financial advice. TENKis not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities TENK rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
SEC correspondence
SEC · UPLOAD / CORRESPDRUG SEC comment-letter history — every letter and response →
SEC staff comment letters (UPLOAD) questioning the company’s disclosures and its written responses (CORRESP), from the SEC’s filing review. Reviews are routine and this is not an assertion of wrongdoing; correspondence is released about 20 business days after a review concludes, so dates reflect the letter itself, not its release. Source: SEC EDGAR (public domain).